News
BarentsKrans again recommended in leading IAM Patent 1000 ranking
The international rankings of ‘IAM Patent 1000’ comprise of an overview of the most prominent law firms in the field of patent law and patent litigation. The listing is composed by means of substantial research by IAM. Firms are assessed on aspects such as knowledge, market share and the quality of rendered services. The assessment
Read more ›
Legal 500 highlights 24 BarentsKrans-laywers in the 2019-edition
This week Legal 500 released their 2019 rankings. As in previous years, BarentsKrans is mentioned several times in this leading, international guide for the legal profession. Again we are beyond proud and grateful of these honourable mentions. Developing Legal 500 rankings Legal 500 highlights those lawyers that provide the most cutting edge and innovative advice
Read more ›
Pharma update: tadalafil patent invalidated
The District Court of The Hague has invalidated ICOS’ patent EP 1 173 181 B3 (‘EP ‘181’) claiming a dosage range of tadalafil for the treatment of sexual dysfunction. Icos Corporation (‘Icos’), an Eli Lilly and Company subsidiary, distributes the medicinal product Cialis® containing tadalafil for the treatment of sexual dysfunction in adult men. EP
Read more ›
Pharma update: Indirect infringement of Swiss type claims is possible
In its judgment of 3 November 2017 in the case between Merck Sharp & Dohme (‘MSD’) and Teva, the Dutch Supreme Court ruled (ECLI:NL:HR:2017:2807) that indirect infringement of a ‘Swiss type’ second medical use patent claim is possible. In addition, the Supreme Court found that there is no difference in the scope of protection of second
Read more ›
Generic Pemetrexed Diacid infringes patent Pemetrexed Disodium
In two judgments of 24 October 2017, the Provisions Judge of the District Court in The Hague held that Teva’s and Fresenius Kabi’s generic pemetrexed diacid products infringe EP 1 313 508 (‘EP ‘508’) of Eli Lilly. EP ‘508 relates to the use of pemetrexed disodium in combination with vitamin B12 for the treatment of certain
Read more ›
Pharma update: MSD and Teva plead on subgroup indication patents
In its decision of 14 July 2015, the Court of Appeal of The Hague had decided that there is a difference in the scope of protection of second medical use patents and subgroup indication patents. On 30 September 2016, Merck Sharp & Dohme (‘MSD’) and Teva pleaded their case before the Dutch Supreme Court. The
Read more ›
